Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048816 | 0.92 | BRD4 (0.39) | SYK | |
| SCHEMBL13048821 | 0.91 | MERTK (0.48) | SYK | |
| SCHEMBL13048207 | 0.87 | SYK (0.54) | SYK | |
| SCHEMBL13048565 | 0.86 | SYK (0.56) | SYKAURKA | |
| SCHEMBL13048564 | 0.85 | SYK (0.56) | SYKAURKACCNB2CDK1CCNB1 | |
| SCHEMBL13048365 | 0.85 | SYK (0.51) | SYKAURKA | |
| SCHEMBL13048601 | 0.85 | MERTK (0.53) | SYKMEN1KMT2AAURKA | |
| SCHEMBL13048626 | 0.83 | SYK (0.45) | SYK | |
| SCHEMBL13048802 | 0.83 | SYK (0.50) | SYKCCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL13048808 | 0.83 | SYK (0.55) | SYKCCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | SYK, LCK, FYN | SYK 1/4885KDM4E 2150/4885MEN1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.